Search Results - "Beebe, Elyse A"

A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93 by Orr, Mark T, Beebe, Elyse A, Hudson, Thomas E, Moon, James J, Fox, Christopher B, Reed, Steven G, Coler, Rhea N

“…With over eight million cases of tuberculosis each year there is a pressing need for the development of new vaccines against Mycobacterium tuberculosis…”
Get full text

Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy by Orr, Mark T, Beebe, Elyse A, E. Hudson, Thomas, Argilla, David, Huang, Po-Wei D, Reese, Valerie A, Fox, Christopher B, Reed, Steven G, Coler, Rhea N

“…Abstract Pulmonary tuberculosis (TB) remains one of the leading causes of infectious disease death despite widespread usage of the BCG vaccine. A number of new…”
Get full text

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach by Fox, Christopher B., Orr, Mark T., Van Hoeven, Neal, Parker, Sarah C., Mikasa, Traci J.T., Phan, Tony, Beebe, Elyse A., Nana, Ghislain I., Joshi, Sharvari W, Tomai, Mark A., Elvecrog, James, Fouts, Timothy R., Reed, Steven G.

“…For nearly a century, aluminum salts have been the most widely used vaccine adjuvant formulation, and have thus established a history of safety and efficacy…”
Get full text

Assessment of Antigen-Specific Cellular Immunogenicity Using Intracellular Cytokine Staining, ELISpot, and Culture Supernatants by Beebe, Elyse A, Orr, Mark T

“…Quantification of cytokine production by CD4 and CD8 T cells after in vitro recall stimulation with the immunizing antigen is a powerful approach to…”
Get more information

Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate by Baldwin, Susan L, Reese, Valerie A, Huang, Po-Wei D, Beebe, Elyse A, Podell, Brendan K, Reed, Steven G, Coler, Rhea N

“…Mycobacterium tuberculosis HN878 represents a virulent clinical strain from the W-Beijing family, which has been tested in small animal models in order to…”
Get full text

Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism by Coler, Rhea N, Hudson, Thomas, Hughes, Sean, Huang, Po-Wei D, Beebe, Elyse A, Orr, Mark T

“…The discovery of new vaccines against infectious diseases and cancer requires the development of novel adjuvants with well-defined activities. The TLR4 agonist…”
Get full text

Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4⁺ T-Cell Responses for Vaccine Control of Tuberculosis by Orr, Mark T., Windish, Hillarie Plessner, Beebe, Elyse A., Argilla, David, Huang, Po-Wei D., Reese, Valerie A., Reed, Steven G., Coler, Rhea N.

“…Background. Mycobacterium tuberculosis infects one third of the world's population and causes >8 million cases of tuberculosis annually. New vaccines are…”
Get full text

Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis by Orr, Mark T, Ireton, Gregory C, Beebe, Elyse A, Huang, Po-Wei D, Reese, Valerie A, Argilla, David, Coler, Rhea N, Reed, Steven G

“…Unlike most pathogens, many of the immunodominant epitopes from Mycobacterium tuberculosis are under purifying selection. This startling finding suggests that…”
Get full text

Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach by Kramer, Ryan M, Archer, Michelle C, Orr, Mark T, Dubois Cauwelaert, Natasha, Beebe, Elyse A, Huang, Po-Wei D, Dowling, Quinton M, Schwartz, Alicia M, Fedor, Dawn M, Vedvick, Thomas S, Fox, Christopher B

“…Adjuvants have the potential to increase the efficacy of protein-based vaccines but need to be maintained within specific temperature and storage conditions…”
Get full text

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization by Orr, Mark T., Kramer, Ryan M., Barnes, Lucien, Dowling, Quinton M., Desbien, Anthony L., Beebe, Elyse A., Laurance, John D., Fox, Christopher B., Reed, Steven G., Coler, Rhea N., Vedvick, Thomas S.

“…Next-generation rationally-designed vaccine adjuvants represent a significant breakthrough to enable development of vaccines against challenging diseases…”
Get full text

Increased protection and decreased lung immunopathology induced by the ID93/GLA-SE vaccine candidate following infection with Mycobacterium tuberculosis HN878 by Baldwin, Susan L, Reese, Valerie A., Huang, Po-wei D., Beebe, Elyse A., Podell, Brendan K., Reed, Steven G., Coler, Rhea N.

“…Mycobacterium tuberculosis (M. tuberculosis) HN878 causes death and extensive lung pathology in infected C57BL/6 mice. A clinically relevant isolate of M…”
Get full text

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93: e83884 by Orr, Mark T, Beebe, Elyse A, Hudson, Thomas E, Moon, James J, Fox, Christopher B, Reed, Steven G, Coler, Rhea N

“…With over eight million cases of tuberculosis each year there is a pressing need for the development of new vaccines against Mycobacterium tuberculosis…”
Get full text